SESN2 and hepatocellular carcinoma: Sorafenib treatment increased the expression of sestrin 2 in human HCC lines Bel-7404 and SNU-368, and knockdown of sestrin 2 enhanced growth inhibition and apoptosis induced by sorafenib.